BRCA1 and breast cancer: Of 828 patients with advanced malignancies including breast cancer undergoing testing with a 73 gene cfDNA assay, one or more pathogenic BRCA1/2 mutation was identified in 7.2% of patients, and both somatic and germline variants were detected.